Related Experiment Video

Updated: Jan 13, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

Sila Oksuz1, Oguzcan Kinikoglu2, Ugur Ozkerim2

  • 1Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, 34865, Istanbul, Turkey. sila.oksuz@gmail.com.

Journal of Cancer Research and Clinical Oncology
|January 8, 2026
PubMed
Abstract

Insights

The Gustave Roussy Immune Score (GRIm Score) predicts response to nivolumab immunotherapy in advanced melanoma. A low GRIm Score is linked to significantly longer progression-free and overall survival, aiding patient stratification.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background:

  • Malignant melanoma is an aggressive skin cancer with high metastatic potential.
  • Immune checkpoint inhibitors (ICIs), like nivolumab, have improved outcomes in advanced melanoma.
  • Predictive biomarkers are crucial for stratifying patients and optimizing ICI therapy.

Purpose of the Study:

  • To evaluate the Gustave Roussy Immune Score (GRIm Score) as a prognostic tool for predicting response to nivolumab monotherapy in stage IV malignant melanoma.
  • To assess the association between the GRIm Score and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective analysis of 40 stage IV malignant melanoma patients treated with nivolumab (2020-2024).
  • Calculation of the GRIm Score based on lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels.
  • Classification of patients into low-risk (score 0-1) and high-risk (score 2-3) groups.

Main Results:

  • Patients with a low GRIm Score demonstrated significantly longer median PFS (21.4 vs. 6.3 months, p=0.003) and OS (26.5 vs. 7.2 months, p<0.001).
  • Multivariate analysis identified the GRIm Score as an independent prognostic factor (HR: 1.593, p=0.004).
  • The GRIm Score showed superior predictive power compared to its individual components.

Conclusions:

  • This study provides the first validation of the GRIm Score in malignant melanoma patients treated with nivolumab.
  • The GRIm Score is a valuable biomarker for patient selection in immunotherapy trials and refining treatment decisions.
  • Further validation in larger, multicenter cohorts is warranted to confirm these findings.
Keywords:
Gustave roussy immune score (GRIm score)Immunotherapy biomarkersMalignant melanomaNivolumab

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645